Published in J Virol on November 01, 1999
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol (2004) 1.44
Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med (2002) 1.18
Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol (2010) 1.15
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J Virol (2004) 1.05
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol (2010) 0.98
Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. J Virol (2010) 0.92
Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol (2009) 0.90
Creation of killer poxvirus could have been predicted. J Virol (2001) 0.89
Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol (2004) 0.89
Viruses, dendritic cells and the lung. Respir Res (2001) 0.84
IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect (2006) 0.84
Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse. PLoS One (2011) 0.80
Cationic liposome-mediated enhanced generation of human HLA-restricted RSV-specific CD8+ CTL+. J Clin Immunol (2002) 0.75
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med (1989) 11.36
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 5.92
Lymphokine production by human T cells in disease states. Annu Rev Immunol (1994) 4.90
Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc Natl Acad Sci U S A (1986) 4.59
Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest (1997) 4.01
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci U S A (1986) 3.56
Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity (1995) 3.23
Transcriptional regulation of the IL-2 gene. Curr Opin Immunol (1995) 3.14
The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol (1993) 2.96
CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med (1992) 2.70
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun (1991) 2.46
Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells. Science (1993) 2.43
The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med (1981) 2.15
B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med (1987) 2.09
Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature (1987) 1.75
Antigen-driven helper cell-independent cloned cytolytic T lymphocytes. Nature (1981) 1.72
A dominant selectable marker for the construction of recombinant poxviruses. Gene (1988) 1.72
Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 1.67
Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 1.55
Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol (1996) 1.52
The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity (1994) 1.49
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J Virol (1993) 1.47
The interleukins. FASEB J (1989) 1.46
Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity (1996) 1.37
Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol (1996) 1.37
Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev (1992) 1.34
Molecular mechanisms underlying functional T-cell unresponsiveness. Curr Opin Immunol (1995) 1.27
Cell-mediated immune response to schistosomiasis. Curr Top Microbiol Immunol (1990) 1.26
Dissection of the proliferative and differentiative signals controlling murine cytotoxic T lymphocyte responses. J Exp Med (1982) 1.20
Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene (1985) 1.18
B cell stimulatory factor 1 (interleukin 4) is sufficient for the proliferation and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Exp Med (1987) 1.17
An antigen receptor-driven, interleukin 2-independent pathway for proliferation of murine cytolytic T lymphocyte clones. J Exp Med (1986) 1.12
T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest (1997) 0.98
B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. J Immunol (1988) 0.95
IL-4 and IL-13 production in differentiated T helper type 2 cells is not IL-4 dependent. J Immunol (1997) 0.90
Enhanced cytotoxic T cell activity in IL-4-deficient mice. J Immunol (1999) 0.84
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (1993) 2.92
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Acute pubic osteomyelitis in athletes. Clin Infect Dis (1992) 2.29
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol (1998) 2.21
High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J Clin Microbiol (2009) 2.13
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 1.79
Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med (1984) 1.76
Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 1.67
Rhodococcus equi--an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. Am J Clin Pathol (1995) 1.66
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 1.55
Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J Infect Dis (1999) 1.54
Features and outcomes of classic heat stroke. Ann Intern Med (1999) 1.54
Serum vitamin A levels in respiratory syncytial virus infection. J Pediatr (1994) 1.53
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis (2001) 1.49
Adult immunization with acellular pertussis vaccine. JAMA (1993) 1.47
Direct identification of bacteria from positive blood cultures by amplification and sequencing of the 16S rRNA gene: evaluation of BACTEC 9240 instrument true-positive and false-positive results. J Clin Microbiol (2001) 1.44
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43
Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol (1999) 1.42
Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome. Clin Infect Dis (2000) 1.40
Treatment of axillary bromhidrosis with superficial liposuction. Plast Reconstr Surg (1998) 1.39
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35
Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J Med Virol (1999) 1.34
A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med (2000) 1.26
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
Comparison of pulsed-field gel electrophoresis and amplified fragment-length polymorphism for epidemiological investigations of common nosocomial pathogens. Infect Control Hosp Epidemiol (2001) 1.15
Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J Virol (2001) 1.15
RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J Virol (1999) 1.14
Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med (2000) 1.12
Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J Infect Dis (2001) 1.12
Myocardial abscess with complete heart block complicating anaerobic infective endocarditis. Br Heart J (1986) 1.11
Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J Med Virol (2001) 1.10
A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J Immunol Methods (2010) 1.10
Hemagglutination-inhibiting antibody in hemorrhagic fever with renal syndrome. J Infect Dis (1984) 1.09
Isolation of haemorrhagic fever with renal syndrome virus from Suncus murinus, an insectivore. Lancet (1985) 1.09
Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis (2000) 1.08
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother (2001) 1.08
Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine (1997) 1.06
Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis (2000) 1.06
Herpes simplex virus infection of the adult lower respiratory tract. Medicine (Baltimore) (1983) 1.05
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol (2012) 1.05
Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J Infect Dis (1993) 1.04
IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J Immunol (2000) 1.03
Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res (1993) 1.02
Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci (1996) 1.02
Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J Infect Dis (1995) 1.01
Dysphagia associated with an aortic arch anomaly in adults. Am Surg (1986) 1.00
Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest (1993) 0.98
RhoA is activated during respiratory syncytial virus infection. Virology (2001) 0.98
T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest (1997) 0.98
Retrospective and prospective studies of hemorrhagic fever with renal syndrome in rural China. J Infect Dis (1994) 0.97
Mycobacterium chelonae: a cause of nodular skin lesions with a proclivity for renal transplant recipients. Am J Med (1989) 0.97
Endocarditis and infections of intravascular devices due to Eikenella corrodens. Am J Med Sci (1986) 0.97
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1997) 0.96
Clinical features, treatments and prognosis of the initial cases of pandemic influenza H1N1 2009 virus infection in Shanghai China. QJM (2010) 0.96
Acid-fast bacilli on buffy coat smears in the acquired immunodeficiency syndrome: a lesson from Hansen's bacillus. South Med J (1984) 0.95
Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor. Thorax (2002) 0.94
A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab (1975) 0.94
Firm elevation of the auricle in reconstruction of microtia with a retroauricular fascial flap wrapping an autogenous cartilage wedge. Br J Plast Surg (2001) 0.92
Pseudomonas aeruginosa causing osteomyelitis after puncture wounds of the foot. South Med J (1984) 0.92
Nonexertional heatstroke. Physiologic management and cooling in 14 patients. Arch Intern Med (1986) 0.92
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1996) 0.90
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol (1992) 0.89
Testicular choriocarcinoma metastatic to the skin: an additional case and literature review. Cutis (2001) 0.89
Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). J Med Primatol (1999) 0.89
Clinical and molecular characterization of vancomycin-resistant Enterococcus faecium strains during establishment of endemicity. Clin Infect Dis (2001) 0.89
Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine (1997) 0.89
Transepidermal migration of external cardiac pacing wire presenting as a cutaneous nodule. J Am Acad Dermatol (2000) 0.87
Blastomycosis presenting as monoarticular arthritis. The role of synovial fluid cytology. Arthritis Rheum (1985) 0.87
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. J Infect Dis (2000) 0.86
Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Acta Paediatr (1996) 0.86
Community dissemination of vancomycin-resistant Enterococcus faecium. Am J Infect Control (2001) 0.84
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol (1994) 0.84
Hemodynamic effects and clinical determinants of defibrillation threshold for transvenous atrial defibrillation using biatrial biphasic shocks in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol (1997) 0.84
Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. J Gen Virol (2001) 0.84
Use of Biobrane in pediatric scald burns--experience in 106 children. Burns (1998) 0.84
Dental soft polymers: plasticizer composite and leachability. Dent Mater (1988) 0.84
Viruses, dendritic cells and the lung. Respir Res (2001) 0.84
Response of cutaneous Rosai-Dorfman disease to topical and intralesional steroids. Br J Dermatol (2003) 0.83
Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. Ann Thorac Surg (1992) 0.83
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann Intern Med (1994) 0.83
Cats--source of protection or infection? A case-control study of hemorrhagic fever with renal syndrome. Am J Epidemiol (1987) 0.83
Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. J Infect Dis (1999) 0.82
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol (1997) 0.82
Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. J Infect Dis (1999) 0.82
A retrospective study of minipercutaneous laser lithotripsy for treatment of allograft kidney lithiasis obstruction. Transplant Proc (2013) 0.82